David Dismuke

David Dismuke is the current Chief Technical Officer at Forge Biologics. Prior to their current position, they served as the Vice President of Manufacturing at StrideBio, Inc from September 2017 to September 2020. In this role, they were responsible for directing the manufacturing and analytical groups, research-grade vector production, upstream and downstream process development, quality control, analytical development, oversight of external cGMP manufacturing, and CMC regulatory filings for rAAV vectors used in lead candidate selection, preclinical studies, and Phase I/II clinical trials.

From September 2014 to August 2017, David Dismuke served as the Director of Vector Production at Voyager Therapeutics, Inc. In this role, they were responsible for directing the manufacturing and analytical groups, research-grade vector production, upstream and downstream process development, quality control, analytical development, oversight of external cGMP manufacturing, and CMC regulatory filings for rAAV vectors used in lead candidate selection, preclinical studies, and Phase I/II clinical trials.

From January 2010 to August 2014, David Dismuke served as the Director of UNC Chapel Hill Vector Core. In this role, they were responsible for research-grade vector production, upstream and downstream process development, quality control, analytical development, oversight of external cGMP manufacturing, and CMC regulatory filings for rAAV vectors used in lead candidate selection, preclinical studies, and Phase I/II clinical trials.

From January 2007 to December 2010, David Dismuke served as a Postdoctoral Research Associate at UNC Gene Therapy Center. In this role, they were responsible for research-grade vector production, upstream and downstream process development, quality control, analytical development, oversight of external cGMP manufacturing, and CMC regulatory filings for rAAV vectors used in lead candidate selection, preclinical studies, and Phase I/II clinical trials.

David Dismuke has a PhD in Microbiology and Immunology from Vanderbilt University. David also has a BA in Chemistry from Carson-Newman University.

They work with Chris Shilling - Vice President of Regulatory Affairs and Quality Assurance, Maria Escolar - Chief Medical Officer, and Erandi de Silva - Co-Founder and Vice President of Product Development. Their manager is Timothy J. Miller, Co-Founder, President and CEO.